Advances in diagnosis and treatment of testicular cancer
Testicular cancer is a curable cancer. The success of physicians in curing the disease is underpinned by multidisciplinary advances. Cisplatin-based combination chemotherapy and the refinement of post-chemotherapy surgical procedures and diagnostic strategies have greatly improved long term survival in most patients. Despite such excellent outcomes, several controversial dilemmas exist in the approaches to clinical stage I disease, salvage chemotherapy, post-chemotherapy surgical procedures, and implementing innovative imaging studies. Relapse after salvage chemotherapy has a poor prognosis and the optimal treatment is not apparent. Recent research has provided insight into the molecular mechanisms underlying cisplatin resistance. Phase 2 studies with targeted agents have failed to show adequate efficacy; however, our understanding of cisplatin resistant disease is rapidly expanding. This review summarizes recent advances and discusses relevant issues in the biology and management of testicular cancer.
Top-30
Journals
|
1
2
3
4
|
|
|
Frontiers in Oncology
4 publications, 6.9%
|
|
|
Cancers
3 publications, 5.17%
|
|
|
Discover Oncology
3 publications, 5.17%
|
|
|
Andrology
3 publications, 5.17%
|
|
|
International Journal of Molecular Sciences
2 publications, 3.45%
|
|
|
European Journal of Cancer Prevention
1 publication, 1.72%
|
|
|
Journal of Cancer Research and Clinical Oncology
1 publication, 1.72%
|
|
|
Pharmaceutics
1 publication, 1.72%
|
|
|
Epigenetics
1 publication, 1.72%
|
|
|
International Urology and Nephrology
1 publication, 1.72%
|
|
|
Cell Death Discovery
1 publication, 1.72%
|
|
|
Die Pathologie
1 publication, 1.72%
|
|
|
Journal of the American Society of Nephrology : JASN
1 publication, 1.72%
|
|
|
Clinical Cancer Research
1 publication, 1.72%
|
|
|
Oncology Letters
1 publication, 1.72%
|
|
|
Cureus
1 publication, 1.72%
|
|
|
European Journal of Radiology
1 publication, 1.72%
|
|
|
Biochemical Pharmacology
1 publication, 1.72%
|
|
|
Diagnostic Histopathology
1 publication, 1.72%
|
|
|
Phytomedicine
1 publication, 1.72%
|
|
|
Medicina
1 publication, 1.72%
|
|
|
Current Opinion in Urology
1 publication, 1.72%
|
|
|
Pathology
1 publication, 1.72%
|
|
|
Environmental Health: A Global Access Science Source
1 publication, 1.72%
|
|
|
International Journal of Africa Nursing Sciences
1 publication, 1.72%
|
|
|
BMJ Case Reports
1 publication, 1.72%
|
|
|
European Urology Focus
1 publication, 1.72%
|
|
|
Frontiers in Pharmacology
1 publication, 1.72%
|
|
|
Cancer Letters
1 publication, 1.72%
|
|
|
1
2
3
4
|
Publishers
|
2
4
6
8
10
12
14
16
|
|
|
Springer Nature
15 publications, 25.86%
|
|
|
MDPI
9 publications, 15.52%
|
|
|
Elsevier
9 publications, 15.52%
|
|
|
Frontiers Media S.A.
5 publications, 8.62%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
4 publications, 6.9%
|
|
|
Wiley
4 publications, 6.9%
|
|
|
Taylor & Francis
1 publication, 1.72%
|
|
|
American Society of Nephrology
1 publication, 1.72%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 1.72%
|
|
|
Spandidos Publications
1 publication, 1.72%
|
|
|
BMJ
1 publication, 1.72%
|
|
|
Georg Thieme Verlag KG
1 publication, 1.72%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 1.72%
|
|
|
American Chemical Society (ACS)
1 publication, 1.72%
|
|
|
SAGE
1 publication, 1.72%
|
|
|
AME Publishing Company
1 publication, 1.72%
|
|
|
2
4
6
8
10
12
14
16
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.